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To the Editor,
There remain a number of uncertainties globally about the 
risks posed to women who are infected with SARS-CoV-2 dur-
ing pregnancy, in particular, whether COVID-19 increases 
the risk of adverse outcomes for mother and baby, and the 
ways in which the virus or immunity to the virus may be 
passed from the pregnant woman or breastfeeding mother 
to her infant. Much of the strongest evidence published 
thus far has been in the form of systematic reviews and 
meta-analyses of observational data [1–3], and little has 
been published on this topic from Africa to date.
There have been a number of registries set up interna-
tionally to capture data from women who have been diag-
nosed with COVID-19 during pregnancy, many of which 
have been instrumental in providing crucial observational 
data about pregnancy outcomes in this cohort. These data 
are, however, limited in that they do not provide sufficient 
insight into the mechanisms underlying the observed out-
comes, highlighting a need for the collection of clinical 
samples in this context.
Recently-published data have also suggested that 
symptomatic women may represent only the tip of the ice-
berg of SARS-CoV-2 infection in pregnancy [4, 5], making 
it possible that registries contain data from only a small 
proportion of true SARS-CoV-2 positive cases, especially in 
countries where mass testing has not yet been adopted. 
It is therefore imperative that asymptomatic pregnant 
women are also screened for the virus in order to capture 
the full breadth of effects of SARS-CoV-2 infection in both 
pregnancy and infancy.
PeriCOVID Africa plans to address these knowledge gaps 
by harnessing the infrastructures already in place for a 
number of large studies in sub-Saharan Africa, including 
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There remain a number of uncertainties globally about the risks posed to women who are infected 
with SARS-CoV-2 during pregnancy. Furthermore, our understanding of the spread of COVID-19 in 
 Sub-Saharan Africa is limited, owing to low testing rates in many parts of the continent. PeriCOVID 
Africa, in  conjunction with the WHO/HRP Alliance, plans to address these knowledge gaps by harness-
ing research infrastructures in place in five sub-Saharan African countries in order to screen more than 
50,000 pregnant women and their infants for SARS-CoV-2, while monitoring pregnancy and neonatal 
outcomes. We anticipate that the results of this study will provide much needed information about the 
risks that SARS-CoV-2 poses to pregnant women and their babies, as well as establishing potential routes 
of mother-to-child transmission.
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PREPARE, PRECISE, BAMBI II and the “Early versus late 
BCG vaccination in HIV-1 exposed infants in Uganda” ran-
domised controlled trial. This platform will screen more 
than 59,000 pregnant women for SARS-CoV-2 infection 
and collect clinical samples and data from mothers and 
babies among a birth cohort of nearly 100,000 women 
and infants in the Gambia, Kenya, Malawi, Mozambique 
and Uganda, with additional data from collaborators in 
South Africa (Figure 1).
This body of work will be carried out in conjunction 
with the World Health Organisation (WHO) and the 
United Nations Development Program (UNDP)-United 
Nations Population Fund (UNFPA)-UNICEF-WHO-World 
Bank Special Program of Research, Development and 
Research Training in Human Reproduction, known as the 
HRP Alliance, who together hosted COVID-19 and preg-
nancy research working group meetings which brought 
together global expertise, enabling the development a 
generic cohort protocol addressing COVID-19 among 
pregnant women and their neonates.
Over a 12-month period, we will collect throat swabs 
(to test for SARS-CoV-2 RNA) and blood samples (for 
SARS-CoV-2 serology [IgM/IgG]) from pregnant women 
presenting for antenatal care at our designated study 
sites, based in primary health care facilities and govern-
ment hospitals in each of the five countries. In alignment 
with the WHO/HRP Alliance’s generic cohort protocol, 
we will then follow these women until delivery where we 
will take further samples including cord blood and nasal 
swabs from the infants to assess for evidence of vertical 
transmission, and will also collect clinical data from all 
enrolled women to determine the relative risk of adverse 
outcomes in women who test positive for SARS-CoV-2 
during pregnancy. All data collected will be integrated 
into existing registries and reported monthly to the 
WHO/HRP Alliance-designated platform so that impor-
tant results can be widely disseminated in real-time.
We anticipate that the results of this study will 
help provide the first vital steps to understanding the 
pathophysiology of the risks that SARS-CoV-2 poses to 
pregnant women and their babies, as well as establish-
ing potential routes of mother-to-child transmission, 
which will inform infection prevention and control 
measures recommended for pregnant and breastfeed-
ing women.
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Figure 1: Research collaborations in sub-Saharan Africa recruiting participants for periCOVID Africa.
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Bergen (CISMAC), Norway 
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Aga Khan University, Kenya and 
King’s College, London (PRECISE) 
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College of Medicine, University of 
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Wellcome Trust Clinical Research 
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London (PRECISE) 
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